Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by barmac6on Mar 09, 2011 4:59pm
150 Views
Post# 18261369

RE: Buyers/Sellers today only

RE: Buyers/Sellers today only

House Positions for HEM from 20110309 to 20110309

Ex House Bought $Value Ave Sold $Value Ave Net $Net
2 RBC 149,300 171,673 1.15 6,900 7,901 1.15 142,400 -163,772
7 TD Sec 133,653 152,144 1.14 8,053 9,085 1.13 125,600 -143,059
9 BMO Nesbitt 31,800 35,466 1.12 3,600 4,104 1.14 28,200 -31,362
19 Desjardins 37,700 43,249 1.15 10,500 11,660 1.11 27,200 -31,589
85 Scotia 27,500 31,520 1.15 3,000 3,312 1.10 24,500 -28,208
13 Instinet 15,300 17,368 1.14 0 15,300 -17,368
80 National Bank 12,600 14,748 1.17 6,200 7,316 1.18 6,400 -7,432
101 Newedge 9,300 10,616 1.14 6,600 7,535 1.14 2,700 -3,081
58 Qtrade 2,000 2,340 1.17 0 2,000 -2,340
81 HSBC 1,000 1,100 1.10 0 1,000 -1,100
90 Barclays 600 698 1.16 0 600 -698
39 Merrill Lynch 1,700 1,928 1.13 1,600 1,780 1.11 100 -148
89 Raymond James 153 175 1.14 133 147 1.11 20 -28
124 Questrade 4,000 4,400 1.10 4,000 4,400 1.10 0 0
33 Canaccord 196,000 215,699 1.10 197,500 217,669 1.10 -1,500 1,970
99 Jitney 4,200 4,652 1.11 16,400 18,384 1.12 -12,200 13,732
79 CIBC 47,780 54,564 1.14 60,800 69,092 1.14 -13,020 14,528
53 Morgan Stanley 0 57,900 66,272 1.14 -57,900 66,272
1 Anonymous 67,200 71,204 1.06 358,600 404,887 1.13 -291,400 333,683
Total 741,786 833,544 1.12 741,786 833,544 1.12 0 0
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse